Sugi Predict

Sugi Predict / Compounds / SCHEMBL7210895

SCHEMBL7210895

SCHEMBL7210895

COc1ccc(S(=O)(=O)CC(O)(CSc2ccc(-c3ccccc3)cc2)C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MMP9 P14780 9/20 0.43
▸ MMP13 P45452 7/20 0.43
▸ MMP1 P03956 5/20 0.43
▸ MMP2 P08253 9/20 0.43
▸ MMP12 P39900 5/20 0.43
▸ MMP3 P08254 5/20 0.43
▸ MMP8 P22894 4/20 0.43
▸ MMP14 P50281 3/20 0.43
▸ MMP16 P51512 2/20 0.43
▸ HSD11B1 P28845 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ PDE4A P27815 1/20 0.42
▸ PDE4B Q07343 1/20 0.42
▸ PDE4C Q08493 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ MMP7 P09237 2/20 0.40
▸ KEAP1 Q14145 1/20 0.39
▸ NFE2L2 Q16236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7210446 0.88 MMP13 (0.50) MMP9MMP13MMP1MMP2MMP12
SCHEMBL7493288 0.83 RAB9A (0.51) MMP9MMP2
SCHEMBL7210638 0.82 MMP13 (0.50) MMP9MMP13MMP1MMP2MMP3
SCHEMBL7424262 0.81 MMP2 (0.50) MMP9MMP13MMP1MMP2MMP3
SCHEMBL7428969 0.81 MMP2 (0.50) MMP9MMP13MMP1MMP2MMP3
SCHEMBL7210802 0.81 MMP2 (0.40) MMP9MMP13MMP1MMP2MMP3
SCHEMBL7212048 0.80 MMP1 (0.45) MMP13MMP1MMP2MMP3MMP14
SCHEMBL7215337 0.79 MMP13 (0.60) MMP9MMP13MMP1MMP2MMP12
SCHEMBL7393371 0.77 MMP13 (0.43) MMP13MMP1MMP2
SCHEMBL7212002 0.74 NPC1 (0.51) MMP9MMP13MMP1MMP2MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030166687-A1 ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY 2003-09-04 — — US disclosed
EP-1037868-B1 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS UPJOHN CO (US) 2003-02-05 — — EP disclosed
US-6437177-B1 DISEASES INVOLVING CONNECTIVE TISSUE DEGRADATION; ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, DERMAL, OR GASTRIC ULCERATION, AND ASTHMA; 2-HYDROXY-2-(PHENYLTHIO) METHYL-3-(4-BUTOXYBENZENESULFONYL)PROPIONIC ACID PHARMACIA & UPJOHN COMPANY 2002-08-20 — — US disclosed
EP-1037868-A2 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2000-09-27 — — EP disclosed
WO-1999026909-A2 ALPHA-HYDROXY, -AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 1999-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166687-A1 ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS MMP1, MMP8, HRH3 MMP9 20/4885MMP13 5/4885MMP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.